NOTVQ (Inotiv) Moat Score: 3/10 (As of Jun. 24, 2026)


What is Inotiv Moat Score?

Inotiv NOTVQ -9.91% Moat Score is 3 as of Jun. 24, 2026. The stock has 4 warning signs investors should review. Among 217 Medical Diagnostics & Research companies, Inotiv ranks better than 76.96% on this metric.

Inotiv has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Inotiv has No Moat: Inotiv operates in a competitive contract research market with limited differentiation and low barriers to entry, resulting in a very weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Inotiv might have No Moat - Very weak/transient advantages.

Inotiv  (OTCPK:NOTVQ) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Inotiv Moat Score Related Terms

NOTVQ vs NDRA, XWEL, ADVB: Moat Score Comparison

For the Diagnostics & Research subindustry, Inotiv's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inotiv Moat Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Inotiv's Moat Score distribution charts can be found below:

* The bar in red indicates where Inotiv's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Inotiv (NOTVQ) has a Moat Score of 3 as of Jun. 24, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Inotiv ranks #50 out of 217 companies in the Medical Diagnostics & Research industry, placing it in the top 23%.
Is Inotiv's Moat Score too high?
Inotiv's current Moat Score is 3. Based on the distribution chart, Inotiv ranks #50 out of 217 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Inotiv's Moat Score compare to NDRA and XWEL?
According to the Medical Diagnostics & Research industry distribution chart, Inotiv ranks #50 out of 217 companies for Moat Score. This places Inotiv in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Diagnostics & Research company?
A good Moat Score depends on the Medical Diagnostics & Research industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Inotiv's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inotiv stock overvalued right now?
Based on GuruFocus' analysis, Inotiv (NOTVQ) is currently considered Possible Value Trap. The stock's GF Value™ is $1.68, compared to a current price of $0.01 — trading 99.4% below its estimated fair value. The current Moat Score is 3. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Inotiv (NOTVQ), the current Moat Score is 3 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Inotiv Business Description

Other Exchanges BS50:Germany
Address 2701 Kent Avenue, West Lafayette, IN, USA, 47906
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.